Posts Tagged: "biotech"

WASHINGTON, DC (December 24, 2009) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on today’s vote by the Senate to pass The Patient Protection and Affordable Care Act of 2009: The health care reform bill passed today by the Senate includes many provisions which serve as early Christmas presents for patients living with debilitating…

For many months we have been hearing about the government attempts to “reform” health care in the United States, and this weekend the United States Senate is actually working, yes Senators working on a weekend, as the contentious debate continues. Even a relatively rare Presidential visit to Capitol Hill is scheduled for later this afternoon, presumably so President Obama can…

In this release, the authors (Kaye Scholer LLP’s Patent Group) update and expand Pharmaceutical and Biotech Patent Law with new discussion of many topics, including double patenting, inequitable conduct, product by process claims, attorneys fees under Hatch-Waxman and more. Table of Contents Table of Authorities Below is a synopsis of the significant updates provided for the Fall of 2009.

Inventors Digest, in cooperation with IPWatchdog, is showcasing several essays deserving of honorable mention.  The first in this series appears below. Inventors Digest held a youth innovation essay contest, in part to celebrate National Inventors Month, last August. The four winning essays are at InventorsDigest.com.  The magazine received and reviewed some 400 essays from across the country. The following illustrate…

A study released today by the Biotechnology Industry Organization (BIO) provides first-of-its-kind data on the importance of university/industry research and development partnerships to the U.S. economy. The study of university technology licensing from 1996 to 2007 shows a $187 billion dollar positive impact on the U.S. Gross National Product (GNP) and a $457 billion addition to gross industrial output, using…

Determining what compounds are obvious under the doctrine of “structural similarity” can be a daunting challenge, even for those of us with a chemistry or pharmaceutical background.  Add the doctrine of “inequitable conduct” to the “structural similarity” brew, and the plot truly thickens.  But there’s enough schizophrenia about the structural differences between one prior art compound called Schmutz X and…

A press release issued earlier today by the Pharmaceutical Care Management Association (PCMA) explained that a new article published in the New England Journal of Medicine (NEJM) urges Congress and the White House to revisit pending biogenerics legislation that would grant biotech companies an a 12-year exclusivity period for biologics. The press release explains that the experts, who are Harvard…

On Thursday morning, August 13, 2009, CNBC aired a segment titled Fixing America’s Health Care System on Squawk Box, which is CNBC’s longest running program.  Appearing on the program were Dr. Scott Gottlieb, who is a former FDA deputy commissioner, Tommy Thompson, former Health & Human Services Secretary and Wisconsin Governor and Jim Greenwood, a former Republican Congressman who is…

Patent Bar Review September 22-26, 2009, New York City In clear, concise, right-to-the-point language, this information-packed course leads you through the intricacies – and around the traps – of the Patent Bar Exam. You’ll get the hard facts, test-taking tips, sample questions and answers, and intense practice exams that mirror what you’re going to face when you sit down to…

Last week, on July 8, 2009, former Presidential Candidate, former Vermont Governor and former Chair of the Democratic National Committee, Howard Dean stepped into the health reform debate, discussing in an Op-ed piece published by TheHill.com. It is not surprising that Dean, who is a Medical Doctor and politician, would attempt to let his positions on health reform be known.…

Until recently the Obama Administration had not taken any particularly strong or controversial stances with respect to intellectual property protection.  Sure, President Obama appointed a former RIAA attorney to a top spot in the Department of Justice, asked for study of open source initiatives for the federal government and has complained about counterfeiting and copyright infringement abroad.  On patent matters…

First, let me say that it is really a complete misnomer to refer to “gene patents” because despite what the popular press may write, and perhaps believe, genes are not patented.  Nevertheless, I will cave into the masses and concede (at least for now) the linguistic high ground and refer to gene-related innovations that are examined by patent authorities and…

There are a lot of crazies coming out of the woodwork with respect to the ACLU’s efforts to have the patent laws of the United States declared unconstitutional.  Perhaps you have heard, the ALCU is standing up for breast cancer patients because Myriad Genetics has patented genes.  How awful really.  Not that Myriad has patented genes, because that is factually…

BioArts International announced today that delivered the world’s first commercially cloned dog, a 10-week old Labrador named Lancey, to Florida residents Edgar and Nina Otto.  According to the press release issued by the company, “BioArts International is a biotech company focused on unique, untapped markets in the global companion animal, stem cell and human genomics industries. The Best Friends Again…